Positions

Selected Publications

Academic Article

Year Title Altmetric
2014 Development and survival of th17 cells within the intestines: The influence of microbiome-and diet-derived signals.  Journal of Immunology.  193:4769-4777. 2014
2013 Allogeneic th1 cells home to host bone marrow and spleen and mediate ifnγ-dependent aplasia.  Biology of Blood and Marrow Transplantation.  19:876-887. 2013

Principal Investigator On

  • 11-TREO: A Phase II Study of Treosulfane/Fiudarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children with AMLIMDS Undergoing Allogeneic Hematopoietic Cell Transplantation  awarded by National Marrow Donor Program
  • A Multi-Center, Randomized, Double-Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD  awarded by NATIONAL CHILDHOOD CANCER FOUNDATION
  • A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients  awarded by New York Blood Center
  • A Phase 1/2 Trial of Uproleselan Combined with High Dose Busulfan Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for Patients with Chemotherapy Resistant Acute Myeloid Leukemia  awarded by DANA-FARBER CANCER INSTITUTE INC
  • Acute GVHD Suppression using Co-Stimulation Blockage to Expand Non-Malignant Transplant (ASCENT)  awarded by Emory University
  • Identifying Predictors of Poor Health Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors  awarded by National Marrow Donor Program
  • PBMTC Study No. 1701 "Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children with B-ALL (Endrad) Trial"  awarded by CHILDREN'S HOSPITAL LA
  • Predictive Biomarkers of Pediatric Graft-Versus-Host Disease  awarded by Canadian Institutes of Health Research
  • Private Grant  awarded by KADMON CORPORATION
  • Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Role of Allogenic Th1 Like Cells in Graft Versus Host Disease and Graft Versus Lukemia  awarded by HYUNDAI HOPE ON WHEELS

    • Investigator On

  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders/ PBMTC PIDTC #6901  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCRaß+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC “CSIDE” Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801  awarded by Childrens Hospital Los Angeles
  • A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants with Severe Combined Immunodeficiency (SCID) Receiving TCRaß+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC “CSIDE” Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801  awarded by University of California, Los Angeles
  • A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Gliomac-UFRA-317  awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Acute GVHD Suppression using Costimulation Blockage to Expand Non-malignant Transplant (ASCENT)  awarded by Emory University
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • HLA Matched Related Hematopoietic Stem Cell Transplantation for Children with Less Severe Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial  awarded by CHILDREN'S HEALTHCARE OF ATLANTA
  • Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease  awarded by Emory University
  • NAPAAC Registry Study of Bone Marrow Failure and Myelodysplastic Syndromes  awarded by BOSTON CHILDREN'S HOSPITAL
  • Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG  awarded by PUBLIC HEALTH INSTITUTE (PHI)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Primary Immune Deficiency Treatment Consortium  awarded by University of California, San Francisco
  • Primary Immune Deficiency Treatment Consortium  awarded by University of California, San Francisco
  • Private Grant  awarded by JAZZ PHARMACEUTICALS, INC.
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by JAZZ PHARMACEUTICALS, INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by ALEXION PHARMACEUTICALS, INC.
  • Private Grant  awarded by ALLOVIR INC.
  • Private Grant  awarded by KADMON CORPORATION
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC.
  • Private Grant  awarded by ALLOVIR INC.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • Project Sickle Cure  awarded by CHILDREN'S HEALTHCARE OF ATLANTA
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program
  • Reduced-Intensity Conditioning for Children and Adults with Hemaphagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Screen to Intervene: Improving Family-Centered Psychosocial Screening  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • The Role of Minimal Residual Disease Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia.  awarded by National Marrow Donor Program
  • Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 0601  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen / BMT CTN Protocol 601  awarded by NATIONAL CHILDHOOD CANCER FOUNDATION

    • Education And Training

  • University of Tennessee College of Medicine, Residency
  • Memorial Sloan Kettering Cancer Center, Postdoctoral Fellowship
  • Memorial Sloan Kettering Cancer Center, Postdoctoral Fellowship
  • Doctor of Medicine, University of South Carolina System : Columbia 1997
  • Bachelor of Science or Mathematics in Chemistry, Davidson College 1993

    • Full Name

  • Joseph Chewning